Satralizumab for children with AQP4-positive NMOSD attacks
Treatments studied
Part of Brain & nervous system, Eyes & vision, Immune system & allergy clinical trials.
This trial studies satralizumab in children ages 2 to 11 with a specific type of NMOSD caused by AQP4 antibodies. It aims to see how well the medicine prevents attacks and is safe over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 2 to 11 at the time of screening
- You weigh at least 10 kilograms (about 22 pounds)
- The diagnosis is NMOSD with AQP4 antibodies (AQP4 positive), using standard criteria
- You had at least one documented NMOSD attack in the past year (this includes the first attack)
- Your nervous system symptoms have been stable for at least 30 days before screening and before baseline
- If you take immune-suppressing medicine, your dose must be steady for 4 weeks before baseline
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares several medications to see which works best for NMOSD, an autoimmune disease that can cause vision loss and paralysis. You must have a specific antibody (AQP4-IgG) to join.
This trial tests a new antibody-based medicine to help people recover from an acute attack of neuromyelitis optica spectrum disorder (NMOSD), a condition that causes inflammation in the eyes and spinal cord. If you are having a recent flare-up and are already getting or planning to get steroid treatment, this study might offer an additional option to reduce damage and speed recovery.
This trial studies whether inebilizumab can reduce illness activity in children with neuromyelitis optica spectrum disorder (NMOSD), a condition that can cause attacks affecting the eyes and spinal cord. It focuses on kids who have had recent relapses, meaning symptoms came back or worsened.
This trial studies ofatumumab to reduce disease activity in adults with AQP4-IgG positive NMOSD who have had recent relapses. It may help lower the chance of new attacks and help prevent worsening disability over time.
This study tests a medicine called ravulizumab to see if it lowers certain proteins in the blood that may indicate nerve damage in people with NMOSD. If you have NMOSD, this study could help track how well the treatment works.
This study tests a new medicine called ravulizumab (an infusion) to reduce relapses in people with neuromyelitis optica spectrum disorder (NMOSD), a rare condition affecting the optic nerve and spinal cord. The trial is specifically enrolling adults in China who have had recent disease activity.
Hear when a new Neuromyelitis Optica Spectrum Disorder trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.